ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Varmus: Why are scientific societies obstructing public access to research results?

May 20, 2005

Gallo Publishes Study to Resolve controversy Over HIV Discovery

March 15, 1991

More Shakeups Coming Cooperative groups; Chairmen Consider Mutimembership Problems

February 20, 1976

Funding opportunities listed.

November 5, 2004

Two OAM Advisors Criticize Third over ACS Membership

July 23, 1993

Survivors With Gene Variant At More Risk For Heart Disease

June 25, 2010